The Association Between Brain Metabolic Biomarkers Using 18 F-FDG and Cognition and Vascular Risk Factors, as well as Its Usefulness in the Diagnosis and Staging of Alzheimer's Disease.

Autor:	Xiong M; Department of Nuclear Medicine, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China., You H; Department of Nuclear Medicine, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China., Liao W; Department of Neurology, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China., Mai Y; Department of Neurology, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China., Luo X; Department of Nuclear Medicine, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China., Liu Y; Department of Nuclear Medicine, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China., Jiang SN; Department of Nuclear Medicine, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Jazyk:	angličtina
Zdroj:	Journal of Alzheimer's disease reports [J Alzheimers Dis Rep] 2024 Sep 05; Vol. 8 (1), pp. 1229-1240. Date of Electronic Publication: 2024 Sep 05 (Print Publication: 2024).
DOI:	10.3233/ADR-240104
Abstrakt:	Background: ¹⁸ F-fluorodeoxyglucose ( ¹⁸ F-FDG) positron emission tomography (PET) is valuable in Alzheimer's disease (AD) workup. Objective: To explore the effectiveness of ¹⁸ F-FDG PET in differentiating and staging AD and associations between brain glucose metabolism and cognitive functions and vascular risk factors. Methods: 107 participates including 19 mild cognitive impairment (MCI), 38 mild AD, 24 moderate AD, 15 moderate-severe AD, and 11 frontotemporal dementia (FTD) were enrolled. Visual and voxel-based analysis procedures were utilized. Cognitive conditions, including 6 cognitive function scores and 7 single-domain cognitive performances, and vascular risk factors linked to hypertension, hyperlipidemia, diabetes, and obesity were correlated with glucose metabolism in AD dementia using age as a covariate. Results: ¹⁸ F-FDG PET effectively differentiated AD from FTD and also differentiated MCI from AD subtypes with significantly different hypometabolism (except for mild AD) (height threshold p < 0.001, all puncorr < 0.05, the same below). The cognitive function scores, notably Mini-Mental State Examination and Montreal Cognitive Assessment, correlated significantly with regional glucose metabolism in AD participants (all p < 0.05), whereas the single-domain cognitive performance and vascular risk factors were significantly associated with regional glucose metabolism in MCI patients (all p < 0.05). Conclusions: This study underlines the vital role of ¹⁸ F-FDG PET in identifying and staging AD. Brain glucose metabolism is associated with cognitive status in AD dementia and vascular risk factors in MCI, indicating that ¹⁸ F-FDG PET might be promising for predicting cognitive decline and serve as a visual framework for investigating underlying mechanism of vascular risk factors influencing the conversion from MCI to AD. Competing Interests: The authors have no conflict of interest to report. (© 2024 – The authors. Published by IOS Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu